Commercial Supply PF-07321332 Paxlovid Related Intermediates with High Quality
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
| Chemical Name | Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate |
| Synonyms | Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate; (αS,3S)-α-[(tert-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic acid Methyl Ester; (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate |
| CAS Number | 328086-60-8 |
| CAT Number | RF-PI317 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C13H22N2O5 |
| Molecular Weight | 286.33 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| Identification A | IR: Similar to Reference Substance |
| Identification B | Retention Time: Similar to Reference Substance |
| Loss on Drying | ≤1.0% |
| Residue on Ignition | ≤0.20% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤2.0% |
| Heavy Metals (Pb) | ≤20ppm |
| Purity | ≥98.0% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate (CAS 328086-60-8) is the intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0). PF-07321332, the key component of Paxlovid (PF-07321332 and Ritonavir) which is an investigational COVID-19 oral antiviral candidate, is an orally bioavailable 3C-like protease (3CLPRO) inhibitor with potent antiviral effects against SARS-CoV-2 virus and COVID-19. On Nove 6th 2021, Pfizer announced that Paxlovid significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. Boceprevir (EBP-520) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection. Boceprevir with pegylated interferon and ribavirin (PegIFN/RBV) enabled improvement in sustained virological response rates of patients with genotype 1 HCV. Boceprevir interacts with immunosuppressive therapy (IT) by inhibiting the cytochrome P450 3A enzyme.